SEPTEMBERASIA BUSINESS OUTLOOK19DECEMBERASIA BUSINESS OUTLOOK19As a dedicated B2B medical device company specializing in InVitro Diagnostics (IVD), Meril prioritizes the accessibility of its devices, particularly in underserved regions with limited healthcare infrastructurethe evolving needs of healthcare professionals and consumers. The company's Research and Development (R&D) process begins with extensive market research and close collaboration with healthcare providers to identify key challenges and opportunities within the medical diagnostics field. "We are continuously upgrading our technology, including the introduction of new projects and products, multiple disease state detection, early diagnostics detection tools, over-the-counter self-tests, and mobile-based applications for continuous basic health and lifestyle monitoring," says Vivek Shah, CEO, Meril life sciences.Ensuring Accuracy & Reliability across all Product SegmentsAccuracy and reliability are at the core of Meril Diagnostics' operations. This commitment is reflected across the company's extensive portfolio, including biochemistry analyzers, hematology systems, coagulation analyzers, HPLC, ELISA platforms, rapid tests, and more. Each of these product segments undergoes a rigorous development process designed to meet the highest medical standards.For instance, Meril's biochemistry analyzers are engineered to deliver precise and consistent results in various clinical settings. These systems are built using high-quality raw materials and advanced technologies that ensure the accurate detection of a wide range of biochemical markers, crucial for diagnosing conditions such as diabetes, liver disorders, and cardiovascular diseases. With its unique compact design, the biochemistry systems offered by Meril Diagnostics prove to be the best in saving recurring costs in laboratory operations. The company's hematology systems, known for their reliability and user-friendly interfaces, are essential tools for detecting blood-related disorders and monitoring patient health. With reagents-saving technology and sturdy designs across 3-part differentiation and 5-part differentiation analyzers, Meril's hematology segment suits laboratories of all levels.Meril's coagulation analyzers, on the other hand, play a pivotal role in diagnosing and managing bleeding disorders. By providing accurate measurements of blood clotting times, these devices help healthcare providers make informed decisions about patient care. Similarly, Meril's HPLC systems have become the new flagship in HbA1c testing with Hb variants flagging allowing major corporate chain labs to offer comprehensive diabetes control reports for the patients and their respective physicians. HPLC systems are becoming crucial for the precise separation, identification, and quantification of various biomolecules, making them indispensable in clinical laboratories.The company's ELISA platforms are designed to detect a wide range of antigens and antibodies, supporting the diagnosis of infectious diseases, vector-borne diseases, thyroid disorders, and other conditions. These platforms are renowned for their sensitivity and specificity, making them invaluable tools in clinical diagnostics. Rapid tests, another significant segment of Meril's portfolio, offer quick and reliable results for various conditions, including infectious diseases and vector-borne diseases across multiple technologies (viz. lateral flow and flow through) offering confidence in screening SEPTEMBERASIA BUSINESS OUTLOOK19
< Page 9 | Page 11 >